SUMMARY Data are presented on a group of cases of primary carcinoma of the bladder, detailing red cell surface blood group antigenic phenotypes, serum haptoglobin phenotypes, and some red cell isoenzyme phenotypes. Account is taken of the stage of the disease at presentation. The results are compared with corresponding phenotype frequencies in groups of presumed healthy persons originating either in Yorkshire or County Durham. Differences in relative incidences were found in the haptoglobin, phosphoglucomutase (PGM), and some other systems. These are both differences between all cases and controls and between particular stages at presentation and controls.
Various studies have been published since 1956 which investigate the relationship between the ABO and a few other blood group systems and bladder cancer.'-" Some of these results are summarised by Mourant et Received for publication 15 September 1982. involved in an epidemiological study of bladder cancer in West Yorkshire, some results of which have been reported elsewhere. '5 16 The entire group is being carefully followed and the disease stage at presentation is known for the majority of patients. The staging is the result of both clinical and histopathological examination and follows the TNM system for bladder cancer17 as follows: The results by sex for the blood groups, serum haptoglobin, and red cell isoenzyme types have been computed, but as there are no statistical differences between the sexes for any system all subsequent results have the sexes pooled. Table 2 gives the results of the phenotype determinations and the corresponding gene frequencies compared with those of the various corresponding Durham control series. The gene frequencies are presented together with a standard error of frequency. Table 3 gives the relative incidence between case and control phenotypes along with the confidence limits and probability levels. The probability column indicates that there is an excess of the B acid phosphatase phenotype when contrasted with the A and BA types and that there are more 21 and 22 phenotypes in the phosphoglucomutase and adenosine deaminase systems. These latter two 
Discussion
Many of the results presented here have not previously been reported and will need confirmation in future studies. The discussion is concerned with the relationship between these genetic blood factors and aetiology. The significance of stage at diagnosis in relation to phenotypic biases is the second major theme.
There is a general point, however, to discuss before a detailed examination of the results, namely, the appropriateness of the control group. The ages of the control group are different from those of the cases, being younger by an average of 10 years. Subdivisions by age strata within cases and controls, however, revealed no statistical differences by age and it is thought unlikely that any significant bias arises from this source.
The controls originate in County Durham rather than the neighbouring area to the south, Yorkshire. There are two factors in the decision to use these particular controls. Control data, analysed at Durham, are available only from 60 hospital patients in Yorkshire. Their results have not been included in this paper, but they are of similar age to the control subjects from Durham and in no system do the results from this small number conflict with the Durham results. Secondly, no larger series for these polymorphisms exists from Yorkshire from any other source.
The biases in the relative incidence of AP, PGM, and ADA types are all new observations which, if confirmed, could be most useful in defining a high risk group susceptible to bladder cancer in the population. They must be considered in relation to our previous report on the bias to the ABO blood group A gene and the S gene of the MNSs system.'4 For example, there will be relatively few people in the general population who have the A phenotype of the ABO system, the SS phenotype of the MNSs system, and the B phenotype of the AP system, perhaps about 1 5% if the systems are distributed independently, while a case group would have these three gene combinations three times more frequently.
The natural history of different cases of bladder cancer, despite broadly similar histopathological appearances, is highly unpredictable and ranges from a well defined fronded tumour which does not invade or return after treatment to a most aggressive disease which invades the bladder wall and spreads rapidly, causing death within months of diagnosis.
There are various ways in which natural histories of bladder cancer may be examined and recorded; these include a subjective assessment of 'degree of aggressiveness' of the tumour based on hospital records of cystoscopies. This was attempted in an early paper" but is poorly reproducible. Alternatively, differential length of survival might be measured, but in the case of the present study several more years of observation would be needed to begin to examine the problem in this fashion. A third approach, which is also useful in a clinical predictive role, is to examine the depth of invasiveness of the tumour at diagnosis. One advantage of this staging procedure is that it is an internationally agreed classification. '7 The carcinoma in situ lesions represent a special case with respect to this classification, however, in that they are potentially highly invasive tumours27 28 which are rare but, where recognised, are regarded as lesions needing aggressive treatment in an attempt to stop deep invasion.
As a measure of natural history, the T system is imperfect but has enough advantages to be considered at length. The Ti and T2 types are a mixture of two types: aggressive lesions and the majority of slow growing lesions, which will rarely cause death. Coupled with this hypothesis are the observations that cigarette smoking is only related as a risk factor to TI and T2 type tumours.29 However, another genetic factor, the phenotypic variants of the liver bound enzyme N-acetyltransferase, has an excess of the slower types associated with T3, T4, and carcinoma in situ. 30 These facts rather suggest that despite its imperfection the T types are useful in subdividing bladder cancer into two general types: the broadly invasive group and the broadly non-invasive.
Returning to the new results presented here, the fact that some gene excesses in PGM, haptoglobin, and esterase are confined to either the TI and T2 or the T3/T4 types is a further confirmation that epidemiological differences probably exist between different T types of bladder cancer.
With respect to the results, it should be remembered that multiple comparisons are inherently dangerous, as some results might be expected to be significant just by chance. A more stringent level of significance of 1 % will still result in the statistically significant excess of the 1 gene in ESD and the PGM and haptoglobin results found in table 5 .
The significance of these results is not readily apparent although it is clear that the cell surface antigenic structure of cells is related to the invasiveness or otherwise of bladder tumours3' with respect to the ABO blood groups, and this might also be the case with other red cell surface markers. In addition, a person's enzymic structure is undoubtedly important in bladder carcinogenesis with respect to N-acetyltransferase30 and this could also be the case with regard to other enzyme systems, the enzymes in the red blood cell being a reflection of their presence in other tissues.
These observations and those on the ABO and MNSs systems14 form the basis of a general approach to the identification of high risk subgroups of the general population. Other studies have paralleled these to find risk occupations and other environmental factors. 15 16 It is the aim of this group of studies in genetics-epidemiology to link all aspects of tumour natural history and environmental exposure in future work with a view to disease control. 
